Jasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Sold by Great Point Partners LLC

Great Point Partners LLC lowered its holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 19.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 322,380 shares of the company’s stock after selling 79,635 shares during the quarter. Jasper Therapeutics makes up about 1.8% of Great Point Partners LLC’s portfolio, making the stock its 20th biggest holding. Great Point Partners LLC’s holdings in Jasper Therapeutics were worth $6,064,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in JSPR. Ikarian Capital LLC purchased a new position in shares of Jasper Therapeutics in the first quarter worth approximately $3,088,000. FMR LLC purchased a new position in shares of Jasper Therapeutics in the third quarter worth approximately $722,000. Bank of New York Mellon Corp purchased a new position in shares of Jasper Therapeutics in the second quarter worth approximately $740,000. AlphaCentric Advisors LLC purchased a new position in shares of Jasper Therapeutics in the third quarter worth approximately $329,000. Finally, Rhumbline Advisers purchased a new position in shares of Jasper Therapeutics in the second quarter worth approximately $300,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Royal Bank of Canada lowered their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research report on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a research report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research report on Thursday, October 24th. JMP Securities reiterated a “market outperform” rating and issued a $70.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, October 15th. Finally, Evercore ISI reiterated an “outperform” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research note on Monday, August 26th. Nine investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $74.86.

Jasper Therapeutics Trading Down 0.4 %

Shares of Jasper Therapeutics stock opened at $22.63 on Wednesday. The firm has a fifty day simple moving average of $20.27 and a 200-day simple moving average of $20.86. Jasper Therapeutics, Inc. has a 1-year low of $4.00 and a 1-year high of $31.01. The stock has a market capitalization of $339.45 million, a price-to-earnings ratio of -4.75 and a beta of 2.19.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.